Company News: Page (1) of 1 - 05/19/17 Email this story to a friend. email article Print this page (Article printing at page facebook

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Sunesis Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm

(May 19, 2017)

LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Sunesis Pharmaceuticals, Inc. (?Sunesis or the ?Company) (Nasdaq: SNSS) concerning possible violations of federal securities laws.

To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or by email at

On May 2, 2017, Sunesis announced that it will withdraw its European Marketing Authorization Application for vosaroxin, its proposed treatment for relapsed/refractory AML. Sunesis stated that its decision followed recent interactions with the European Medicine Agencys Committee for Medicinal Products for Human Use, in which it learned that the committee was likely to adopt a negative opinion in its evaluation of the product.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125

Page: 1

Related Keywords:
Related Sites: DMN Newswire
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved